The first-in-class KRAS G12C inhibitor sotorasib has demonstrated early, deep, and durable responses in the treatment of advanced NSCLC with KRAS G12C mutations, according to results from the registrational phase II CodeBreaK 100 trial. “Breakthrough therapy designation was granted by U.S. Food and Drug Administration (FDA), and I am pleased to report that regulatory filings…